Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

IDT Biologika

- PMLiVE

AstraZeneca shares promising phase 3 results for Imfinzi in bladder cancer

More than 614,000 people are diagnosed with bladder cancer globally every year

- PMLiVE

AstraZeneca’s Imfinzi recommended by CHMP to treat small cell lung cancer

Approximately 30% of small cell lung cancer patients have limited-stage disease

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu granted FDA approval in breast cancer

More than 300,000 cases of breast cancer are diagnosed in the US every year

- PMLiVE

AstraZeneca/Daiichi Sankyo survey reveals breast cancer misconceptions in Europe

The questionnaire gathered insights from 7,750 adults across five countries

- PMLiVE

WHO urges US to ‘reconsider’ withdrawal from global health organisation

President Donald Trump said the agency mishandled the COVID-19 pandemic and other global health crises

- PMLiVE

AstraZeneca receives NICE recommendations for lung cancer drugs Tagrisso and Imfinzi

More than 49,000 people are diagnosed with lung cancer in the UK each year

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Datroway granted FDA approval in breast cancer

More than 300,000 cases of breast cancer are diagnosed in the US every year

- PMLiVE

AstraZeneca’s Calquence granted FDA approval in untreated mantle cell lymphoma

More than 27,500 people worldwide are affected by the rare form of non-Hodgkin lymphoma

- PMLiVE

AstraZeneca’s Lynparza recommended by NICE to treat advanced breast cancer

BRCA1 and BRCA2 mutations are responsible for 52% and 32% of hereditary breast cancer cases, respectively

- PMLiVE

AstraZeneca’s Tagrisso granted EC approval in EGFR-mutated lung cancer

More than 450,000 people are diagnosed with lung cancer each year in Europe

- PMLiVE

AstraZeneca’s Imfinzi granted FDA approval in limited-stage small cell lung cancer

Small cell lung cancer accounts for approximately 15% of all lung cancer diagnoses

- PMLiVE

Sanofi receives FDA fast track designation for COVID-19/flu combination vaccines

The combined vaccine approach could simplify immunisation practices and lead to higher uptake

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links